Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy
NCT05186818Phase 3Completed
- Sponsor
- Cytokinetics
- Start
- Feb 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of aficamten in hypertrophic cardiomyopathy (HCM), sponsored by Cytokinetics. Started Feb 2022; status: completed.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT05186818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05186818.